The observed effects of statins on PCSK9, and the discovery of the connection between loss-of-function (LOF) mutations of PCSK9, hypocholesterolemia, and a decreased risk of developing cardiovascular diseases (CVD) [15,16], justified the manufacturing of PCSK9 inhibitors for the treatment of hypercholesterolemia [17]. The gene discussed is PCSK9; the disease is Hypocholesterolemia.